Navigation Links
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Date:11/9/2007

dy.

Key Findings to Date from the Phase 2 Study

In June 2006, HGS reported the 52-week results of the Phase 2 trial of LymphoStat-B in patients with SLE. The 52-week results demonstrated that LymphoStat-B significantly reduced disease activity versus placebo in patients with serologically active SLE across multiple clinical measures, exhibited clinically relevant biological activity, and appeared generally safe and well tolerated. Frequency and severity of adverse events were similar to placebo, with no increase at higher doses. Among the findings at Week 52 was a significantly improved response rate among serologically active patients, as defined by an improvement in SELENA SLEDAI score of 4 points or greater, no new BILAG A flare and no more than one new BILAG B flare, and no worsening in Physician's Global Assessment (46% for LymphoStat-B versus 29% for placebo, p<0.01). This combination of measures is the primary efficacy endpoint in the ongoing pivotal Phase 3 clinical trials.

The data presented today at ACR 2007 demonstrated that LymphoStat-B achieved sustained improvement or stabilization of SLE disease activity in serogically active patients through 2.5 years. LymphoStat-B also decreased the frequency of SLE disease flares in these patients over time. The overall incidence of adverse events and laboratory abnormalities remained stable or decreased from Week 52 to Week 128.

The evidence of sustained clinical effect in serologically active SLE patients from Week 52 to Week 128 includes:

-- An increase from 46% to 54% in the combined patient response rate

selected as the primary efficacy endpoint of the Phase 3 trials. Among

serologically active subjects who completed 128 weeks of treatment

(n=175), 63% responded based on this measure of clinical effect.

-- An increase from 49% to 58% in the proportion of patients who had

improvement in SLE disease activity, as measured by SELENA SLEDAI'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Reserve" May Also Affect,Alzheimer's Risk -, WASHINGTON, June ... treating risk factors for heart disease and stroke,such ... the progression,of Alzheimer's disease, according to research reported ... Prevention,of Dementia in Washington, DC. , Two new ...
... Jun 09, 2007 (MARKET WIRE via COMTEX ... owned subsidiary of Endo,Pharmaceuticals Holdings Inc. (NASDAQ: ... randomized, double-blind, placebo-controlled,clinical trial evaluating Frova (frovatriptan ... treatment in women with,difficult-to-treat menstrual migraine (MM). ...
Cached Medicine Technology:Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7
(Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... 25 The HHS Office of HIV/AIDS Policy,s AIDS.gov will ... with a special focus on reducing HIV/AIDS-related stigma and promoting ... World AIDS Day will also mark the second anniversary of ... and resources. , , AIDS.gov ...
... guide treatment choices, researchers say , , TUESDAY, Nov. 25 ... genetic model for predicting the risk of recurrence in ... a team at the Duke Institute for Genome Science ... to chemotherapy and targeted therapy regimens. , The researchers ...
... available in Spanish . , A new ... the first time since the report was first issued in ... are decreasing for both men and women, driven largely by ... The report notes that, although the decreases in overall ...
... , , HARRISBURG, Pa., Nov. ... West Middlesex Area School District, the Pennsylvania Department of Health ... Middlesex Junior/Senior High School on Nov. 19 and Nov. 24. ... tetanus/diphtheria/pertussis vaccine was given to approximately 560 parents, students, and ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on Tuesday, December 2, 2008 at,noon Eastern Time. The ... through a link on the investors section of Gen-Probe,s website ... days following,the event. , ...
... with chronic obstructive pulmonary disorder must weigh risks, benefits, ... A new review of existing data confirms that some ... with the lung disease known as chronic obstructive pulmonary ... raise the risk of pneumonia in patients with COPD, ...
Cached Medicine News:Health News:HHS' AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008 2Health News:Gene Test Could Predict Colon Cancer's Return 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 2Health News:Annual report to the nation finds declines in cancer incidence and death rates 3Health News:Annual report to the nation finds declines in cancer incidence and death rates 4Health News:Annual report to the nation finds declines in cancer incidence and death rates 5Health News:Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 2Health News:Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients 3
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
... The SPOTCHEM EZ is a small bench ... Testing is performed on reagent strips with results ... is 48 tests per hour. The instrument accepts ... the swipe of a magnetic card. At the ...
... Veriteq's Refrigerator and Freezer Monitoring ... monitoring system for refrigerators and ... install. Using a building's existing ... Freezer monitoring solution automates the ...
The ThermaViewer™ is constructed and engineered for use in laboratories, hospitals, and commercial kitchens to monitor and document freezer and refrigerator temperatures where inventory is store...
Medicine Products: